Compare Amgen, Inc. (AMGN) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Workiva Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Workiva Inc trades at $52.9 (market cap $2.93B). The key difference: Amgen, Inc. is far larger — about 66.9× Workiva Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| AMGN | WK | |
|---|---|---|
Market Cap | $196.12B | $2.93B |
Sector | Health | Technology |
52-Week High | $388.16 | $93.31 |
52-Week Low | $271.18 | $44.31 |
Enterprise Value | $241.41B | $2.86B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Workiva (WK) trades at $52.17, down slightly by 0.31% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.77 surpassing estimates. Revenue growth is solid, projected to reach $926 million in 2026, though profitability remains thin with a net margin of 1.53%. Recent news highlights investor conference participation and AI integration in financial reporting.
The stock presents growth potential with a consensus price target of $71.00, implying significant upside. However, high valuation multiples (P/E of 217.38) and reliance on sustained earnings expansion pose risks. Competitive pressures in regulatory software and macroeconomic sensitivity could challenge future performance. Institutional ownership trends and continued execution on guidance will be critical for maintaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
